Failure of omalizumab for treatment of severe adult atopic dermatitis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16021135.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.
Medical subject headings
- Antibodies, Monoclonal
- Dermatitis, Atopic